Lenalidomide-d5 is intended for use as an internal standard for the quantification of lenalidomide by GC- or LC-MS. Lenalidomide is related to thalidomide and, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.1 It also induces proliferation and enhances the functional capacity of T lymphocytes, amplifying co-stimulatory signaling pathways.2 Lenalidomide is effective in hematologic cancers, including lymphomas and myelomas.3,4
1.Kim, K., An, S., Cha, H.J., et al.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cellsOncol.Lett.5(2)588-596(2013) 2.McDaniel, J.M., Pinilla-Ibarz, J., and Epling-Burnette, P.K.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesAdv. Hematol.513702(2012) 3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012) 4.Merli, M., Ferrario, A., Basilico, C., et al.Novel agents in indolent lymphomasTher.Adv.Hematol.4(2)133-148(2013)